



SPONSOR: Sen. Hocker & Rep. Briggs King  
Sens. Buckson, Mantzavinos, Pettyjohn, Sokola, Wilson;  
Reps. Baumbach, Dukes, Gray, K. Johnson, Morrison,  
Parker Selby, Ramone

DELAWARE STATE SENATE  
152nd GENERAL ASSEMBLY

SENATE CONCURRENT RESOLUTION NO. 47

PROCLAIMING MAY 2023 "CYSTIC FIBROSIS AWARENESS MONTH" IN THE STATE OF DELAWARE.

1 WHEREAS, cystic fibrosis is an inherited chronic disease that affects the lungs and digestive system of about  
2 40,000 children and adults in the United States and over 70,000 worldwide; and

3 WHEREAS, an estimated 105,000 people are diagnosed with cystic fibrosis across 94 countries; and

4 WHEREAS, more than 75% of patients are diagnosed by age two; and

5 WHEREAS, more than half of the cystic fibrosis patient population is age 18 or older; and

6 WHEREAS, in the 1950s, few children with cystic fibrosis lived to attend elementary school; and

7 WHEREAS, today, because of improved medical treatments and care, more than half of people with cystic fibrosis  
8 are 18 and older, and many people can expect to live healthy, fulfilling lives into their 30s, 40s, and beyond; and

9 WHEREAS, based on the 2022 CF Foundation Patient Registry data, the life expectancy of people with CF who  
10 are born between 2018 and 2022 is predicted to be 56 years; and

11 WHEREAS, advancements in research and medical treatments have further enhanced and extended the lives of  
12 children and adults with cystic fibrosis; and

13 WHEREAS, through the drug development pipeline of the Cystic Fibrosis Foundation, significant progress has  
14 been achieved in the search for new treatments and a cure for this disease is being developed; and

15 WHEREAS, in 2018, the FDA approved the use of lumacaftor/ivacaftor for children with cystic fibrosis ages 12 to  
16 24 months, which allowed about 1,300 additional children in the U.S. to be eligible to receive the drug, bringing the total  
17 number of those in the U.S. who could benefit from the treatment to approximately 12,300; and

18 WHEREAS, the FDA approved Trikafta, the first triple combination therapy available to treat patients with the  
19 most common cystic fibrosis mutation in 2019; and

20 WHEREAS, the theme of this year's cystic fibrosis awareness is "Unity in the Community" to promote public  
21 awareness and understanding of cystic fibrosis and to bring more support for critical research to achieve the goals of  
22 enhancing research programs and finding a cure.

23 NOW, THEREFORE:

24 BE IT RESOLVED by the Senate of the 152nd General Assembly of the State of Delaware, the House concurring  
25 therein, that May 2023 is proclaimed "Cystic Fibrosis Awareness Month" in the State of Delaware.  
26 BE IT FURTHER RESOLVED that a suitably prepared copy of this resolution be presented to the Cystic Fibrosis  
27 Foundation.

SYNOPSIS

This Senate Concurrent Resolution proclaims May 2023 "Cystic Fibrosis Awareness Month" in the State of Delaware.

Author: Senator Hocker